Médecins Sans Frontières (MSF/Doctors Without Borders) have announced that the phase II/III trial of a 6-month multidrug regimen for multidrug-resistant tuberculosis (MDR-TB) has been stopped early as it was ascertained by an independent data safety and monitoring board (DSMB) that the multidrug regimen was superior to current therapy, stated a press release.

The TB PRACTECAL trial compared the local standard of care with a 6-month regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin. The interim analysis involved 242 patients and the randomized controlled trial was done in Belarus, South Africa, and Uzbekistan. The preliminary data will be shared with the World Health Organization (WHO) and will be submitted to a peer reviewed journal as well… (Medscape)